Illuccix

Gozetotide, the active ingredient in Illuccix, is a therapeutic agent presented as an intravenous formulation for clinical use. Its specific therapeutic applications have not been publicly disclosed, and it is administered under professional supervision.

GNH USA supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality, traceability and regulatory compliance across all markets. Illuccix is distributed through a secure cold‑chain logistics network to maintain product integrity during transport.

Illuccix (Gozetotide) is an investigational intravenous agent; at present, no approved therapeutic indications have been publicly disclosed.

- No publicly disclosed indication: The product has not been approved for any specific therapeutic use.